Cambridge spin-out developing oncology drugs based on RNA epigenetics (METTL3 inhibitor).
| Date | Round | Amount |
|---|---|---|
| Apr 2026 | Series C STORM Therapeutics closed a $56M Series C entirely from existing investors to start the Phase 2 trial of its oncology drug STC-15. | $56M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.